Brain+ Transitions Leadership: A New Era for Dementia Care
April 18, 2025, 11:17 am
In the heart of Copenhagen, a significant shift is underway at Brain+ A/S. The company has appointed Devika Wood, its Chief Commercial Officer, as the new CEO. This move marks a pivotal moment in the company’s evolution from a research-focused entity to a commercially driven healthtech powerhouse.
Devika Wood steps into her new role with a robust background in healthtech sales. Her experience in the UK and US markets is invaluable. Under her leadership as CCO, Brain+ has already made strides in the UK care market, particularly with its Ayla dementia care platform. This platform aims to revolutionize non-pharmacological dementia care, offering a lifeline to those affected by this challenging condition.
The transition is not just a change in title; it symbolizes a broader strategy. Brain+ is shedding its research-heavy past. The company is now focused on scaling its commercial operations. The appointment of a commercially savvy CEO is a natural progression. It’s like changing gears in a car; the company is ready to accelerate.
Devika’s track record speaks volumes. She has successfully built a sales pipeline exceeding €600,000 in the UK. This achievement includes securing the first commercial partnership with Southcare Homes, a notable player in dementia care. Her knowledge of private care home systems and NHS commissioning positions her perfectly to drive Brain+ forward.
Kim Baden-Kristensen, the co-founder and former CEO, will remain with the company as a Strategic Advisor. His continued involvement ensures stability during this transition. He will focus on strategic development and investor relations, helping to steer the company through its scale-up phase. This partnership between Kim and Devika is crucial. It’s like a seasoned captain handing over the helm to a skilled first mate, ensuring the ship stays on course.
Brain+ is poised for growth. Recently, the company raised DKK 8 million, allowing it to streamline operations and focus on sales. This financial boost, combined with a leaner organizational structure, sets the stage for increased sales in both private and public care sectors in the UK. The company is not just aiming to participate in the market; it intends to lead it.
The new CEO’s vision is clear. Devika aims to sharpen the company’s focus on commercial execution and UK market expansion. Her commitment to improving dementia care is personal. She understands the impact of dementia on individuals and families. This passion fuels her drive to realize the full potential of the Ayla platform.
As Brain+ enters this new chapter, it faces challenges. The healthtech landscape is competitive. However, with a solid strategy and a dedicated team, the company is well-equipped to navigate these waters. The expansion of the UK commercial team, including the addition of a Business Development Manager, signals a proactive approach to building momentum.
The appointment of Devika Wood as CEO is not just a change in leadership; it’s a declaration of intent. Brain+ is ready to transform dementia care. The company is on a mission to become a category leader. This ambition is supported by a validated service model and an updated commercial strategy.
In the coming months, Brain+ will focus on converting its growing sales pipeline into tangible results. The company’s commitment to delivering impact in dementia care is unwavering. As it scales operations, Brain+ aims to make a meaningful difference in the lives of those affected by dementia.
The transition also highlights the importance of strategic leadership in healthtech. Companies in this sector must adapt quickly to changing market dynamics. Brain+ is setting an example by prioritizing commercial expertise at the highest level. This approach could serve as a blueprint for other healthtech firms looking to thrive in a competitive environment.
In conclusion, Brain+ is at a crossroads. The appointment of Devika Wood as CEO is a bold step towards a brighter future. With a focus on commercial growth and a commitment to improving dementia care, the company is ready to make waves. The journey ahead will be challenging, but with the right leadership and vision, Brain+ is well-positioned to emerge as a leader in the healthtech space. The future of dementia care is bright, and Brain+ is leading the charge.
Devika Wood steps into her new role with a robust background in healthtech sales. Her experience in the UK and US markets is invaluable. Under her leadership as CCO, Brain+ has already made strides in the UK care market, particularly with its Ayla dementia care platform. This platform aims to revolutionize non-pharmacological dementia care, offering a lifeline to those affected by this challenging condition.
The transition is not just a change in title; it symbolizes a broader strategy. Brain+ is shedding its research-heavy past. The company is now focused on scaling its commercial operations. The appointment of a commercially savvy CEO is a natural progression. It’s like changing gears in a car; the company is ready to accelerate.
Devika’s track record speaks volumes. She has successfully built a sales pipeline exceeding €600,000 in the UK. This achievement includes securing the first commercial partnership with Southcare Homes, a notable player in dementia care. Her knowledge of private care home systems and NHS commissioning positions her perfectly to drive Brain+ forward.
Kim Baden-Kristensen, the co-founder and former CEO, will remain with the company as a Strategic Advisor. His continued involvement ensures stability during this transition. He will focus on strategic development and investor relations, helping to steer the company through its scale-up phase. This partnership between Kim and Devika is crucial. It’s like a seasoned captain handing over the helm to a skilled first mate, ensuring the ship stays on course.
Brain+ is poised for growth. Recently, the company raised DKK 8 million, allowing it to streamline operations and focus on sales. This financial boost, combined with a leaner organizational structure, sets the stage for increased sales in both private and public care sectors in the UK. The company is not just aiming to participate in the market; it intends to lead it.
The new CEO’s vision is clear. Devika aims to sharpen the company’s focus on commercial execution and UK market expansion. Her commitment to improving dementia care is personal. She understands the impact of dementia on individuals and families. This passion fuels her drive to realize the full potential of the Ayla platform.
As Brain+ enters this new chapter, it faces challenges. The healthtech landscape is competitive. However, with a solid strategy and a dedicated team, the company is well-equipped to navigate these waters. The expansion of the UK commercial team, including the addition of a Business Development Manager, signals a proactive approach to building momentum.
The appointment of Devika Wood as CEO is not just a change in leadership; it’s a declaration of intent. Brain+ is ready to transform dementia care. The company is on a mission to become a category leader. This ambition is supported by a validated service model and an updated commercial strategy.
In the coming months, Brain+ will focus on converting its growing sales pipeline into tangible results. The company’s commitment to delivering impact in dementia care is unwavering. As it scales operations, Brain+ aims to make a meaningful difference in the lives of those affected by dementia.
The transition also highlights the importance of strategic leadership in healthtech. Companies in this sector must adapt quickly to changing market dynamics. Brain+ is setting an example by prioritizing commercial expertise at the highest level. This approach could serve as a blueprint for other healthtech firms looking to thrive in a competitive environment.
In conclusion, Brain+ is at a crossroads. The appointment of Devika Wood as CEO is a bold step towards a brighter future. With a focus on commercial growth and a commitment to improving dementia care, the company is ready to make waves. The journey ahead will be challenging, but with the right leadership and vision, Brain+ is well-positioned to emerge as a leader in the healthtech space. The future of dementia care is bright, and Brain+ is leading the charge.